Osimertinib (Tagrisso, Astra Zeneca) 4 (Chart 1), an oral EGFR inhibitor with very high brain penetration properties, was able, in preclinical evaluation, to significantly inhibit the growth of six GBM cell lines [41]. The gene discussed is EGFR; the disease is glioblastoma.